Phase II study of Docetaxel and CDDP and 5-FU for metastatic esophageal cancer
Phase 2
- Conditions
- Patients to be registered Esophageal cancer with distant metastasis (Stage IVb or stage IVa with N4)
- Registration Number
- JPRN-UMIN000000821
- Lead Sponsor
- OGSG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) severe disorders in The other organs(cardiac disorder, pulmonary fibrosis or interstitial pneumonia, Liver dysfunction) 2) brain metastasis with symptoms 3) edema which needs treatment 4) severe infectious disease 5) with high fever upper than 38 0C 6) with active double cancer 7) women under pregnancy and/or nursing or women who expects pregnancy 8) with a history of severe allergic reaction against medicines 9) uncontrolled cavity fluid in the chest, abdomen or heart 10) doctor's decision not to register to this regimen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method feasibility, survival period, survival time before progression (Time To Progression: TTP)